Abstract
Sitagliptin and glipizide added to metformin provided similar degrees of glycemic efficacy in patients with type 2 diabetes with inadequate glycemic control on metformin monotherapy at 1 year; however, significantly more patients in the sitagliptin group achieved an A1C reduction of >0.5% without hypoglycemia and without an increase in body weight.
Trial registration:
ClinicalTrials.gov NCT00094770.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Dipeptidyl-Peptidase IV Inhibitors / adverse effects
-
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
-
Double-Blind Method
-
Female
-
Glipizide / adverse effects
-
Glipizide / therapeutic use*
-
Glycated Hemoglobin / metabolism*
-
Humans
-
Hypoglycemia / chemically induced*
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / therapeutic use*
-
Male
-
Metformin / adverse effects
-
Metformin / therapeutic use
-
Middle Aged
-
Pyrazines / adverse effects
-
Pyrazines / therapeutic use*
-
Sitagliptin Phosphate
-
Triazoles / adverse effects
-
Triazoles / therapeutic use*
-
Weight Gain / drug effects*
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Pyrazines
-
Triazoles
-
Metformin
-
Sitagliptin Phosphate
-
Glipizide
Associated data
-
ClinicalTrials.gov/NCT00094770